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Abstract 
Purpose: Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial 
therapy leads to multidrug resistance and inappropriate treatments. We therefore evaluated the cost‑effectiveness of 
direct molecular detection of pathogens in blood for patients with severe sepsis (SES), febrile neutropenia (FN) and 
suspected infective endocarditis (SIE).
Methods: Patients were enrolled in a multicentre, open‑label, cluster‑randomised crossover trial conducted dur‑
ing two consecutive periods, randomly assigned as control period (CP; standard diagnostic workup) or intervention 
period (IP; additional testing with  LightCycler®SeptiFast). Multilevel models used to account for clustering were strati‑
fied by clinical setting (SES, FN, SIE).
Results: A total of 1416 patients (907 SES, 440 FN, 69 SIE) were evaluated for the primary endpoint (rate of blood 
MD). For SES patients, the MD rate was higher during IP than during CP [42.6% (198/465) vs. 28.1% (125/442), odds 
ratio (OR) 1.89, 95% confidence interval (CI) 1.43–2.50; P < 0.001], with an absolute increase of 14.5% (95% CI 8.4–20.7). 
A trend towards an association was observed for SIE [35.4% (17/48) vs. 9.5% (2/21); OR 6.22 (0.98–39.6)], but not for 
FN [32.1% (70/218) vs. 30.2% (67/222), P = 0.66]. Overall, turn‑around time was shorter during IP than during CP (22.9 
vs. 49.5 h, P < 0.001) and hospital costs were similar (median, mean ± SD: IP €14,826, €18,118 ± 17,775; CP €17,828, 
€18,653 ± 15,966). Bootstrap analysis of the incremental cost‑effectiveness ratio showed weak dominance of inter‑
vention in SES patients.
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Take‑home message: Direct detection by PCR of bacterial and 
fungal DNA increases the number of patients with confirmed microbial 
aetiology of severe sepsis, and appropriate antimicrobial therapy can be 
given more rapidly. Molecular detection of pathogens was shown to be 
cost‑effective when performed in addition to blood cultures in patients 
with severe sepsis.
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Introduction
The incidence of sepsis is rising and the severe forms 
[severe sepsis (SES) including septic shock] are still a 
major cause of death [1, 2]. Patients requiring immu-
nosuppressive therapy are more prevalent with febrile 
neutropenia (FN) being a frequent life-threatening com-
plication [3]. Infective endocarditis is also increasing in 
incidence, with high mortality and morbidity [4, 5]. Early 
initiation of appropriate antimicrobial therapy reduces 
the morbidity and mortality of these severe infections, 
prompting the prescription of broad-spectrum antimi-
crobial agents before the results of microbiological diag-
nosis (MD) are known [6–8]. This empirical first-line 
therapy is one of the factors explaining the increase in 
antimicrobial-resistance prevalence [9]. Moreover, anti-
microbial therapy usually remains empirical, since micro-
bial documentation in the blood is usually obtained for 
a maximum of 30% of cases for FN, and 35–50% for SES 
[10–13].
Blood cultures (BC) are still the main biological tools 
for identifying the microbial pathogen(s) associated with 
severe infections [14]. Their results are critical for the 
choice of an appropriate antimicrobial treatment, espe-
cially in cases of resistant bacteria [2, 15, 16]. However, 
their low positivity rates (10–20% overall) and delayed 
results (median 2–3  days) make them useful mostly for 
escalation or de-escalation in the days following the onset 
of sepsis [17, 18]. Molecular detection has been devel-
oped to provide a shorter time to results and to detect 
microbial nucleic acids in patients with receipt of anti-
biotic therapy [12]. Meta-analyses for testing molecular 
detection of pathogen in the blood have reported these 
tests as less sensitive and less specific than BCs, taken as 
the gold standard, and consequently these tests are rarely 
used in the diagnostic standard workup [19, 20]. It should 
be noted that in the previous studies, many cases were 
shown with positive molecular tests and BC-negative 
with clinical status showing signs of bloodstream infec-
tions [21, 22]. The cost-effectiveness of molecular direct 
testing in blood remains unknown [23].
We conducted a multicentre open-label cluster-ran-
domised crossover clinical trial to assess the clinical 
and economic impact of molecular detection of patho-
gens in blood for patients with severe infections, such 
as SES, FN, and suspicion of infective endocarditis (SIE) 
[24]. Our hypothesis was that molecular direct testing, 
in addition to a conventional workup, would provide rel-
evant and timely information for the adjustment of anti-
microbial therapy and that the additional cost would be 
offset by successful infection management.
Methods
Study procedures and participants
The study was conducted in 55 clinical wards of 18 uni-
versity hospitals (each hospital being a cluster) during 
two consecutive 6-month periods, randomly assigned as 
intervention (IP) or control (CP) (standard care) periods. 
Details of the protocol are provided in the supplementary 
text and at the clinical trials website (https://clinicaltrials.
gov NCT00709358). Patients aged ≥18  years were con-
secutively enrolled when meeting the diagnosis of (1) 
SES (including septic shock) [1, 10] (2) a first episode of 
FN [3, 13] or (3) suspicion of infective endocarditis, as 
defined below.
During the two periods, at least two BC sets were col-
lected within 24 h after inclusion [14]. During IP, direct 
molecular testing was additionally performed on blood 
using the CE-IVD  LightCycler® SeptiFast test (LSF; 
Roche Diagnostics, Meylan, France) (see supplemental 
methods for details on testing). During the two periods, 
additional BCs and other specimens were submitted for 
microbiological examination at the discretion of the phy-
sician and processed following general guidelines [14]. 
The results of microbiological tests, including LSF tests 
during IP, were transmitted to clinical wards in a time-
line for physicians to initiate or modify antimicrobial 
therapy following general recommendations [3, 7, 25].
Endpoints
The primary endpoint was MD, i.e. detection of patho-
gens in the blood samples using results of BCs during CP 
and of both BCs and molecular tests during IP.
Secondary endpoints included the pathogens identi-
fied, the turn-around time (TAT) (i.e., time interval from 
taking blood samples to transmission of results), and 
the number of patients receiving an appropriate treat-
ment. Appropriateness was evaluated by comparing the 
pathogen detected and the list of antimicrobial agents 
prescribed within the 7 days after inclusion [3, 7, 25]. The 
complications were observed until the end of the study 
(EOS) (discharge, death, 30 days for SES and FN, 45 days 
for SIE). Costs were measured at the EOS.
Conclusion: Addition of molecular detection to standard care improves MD and thus efficiency of healthcare 
resource usage in patients with SES.
ClinicalTrials.gov registration number: NCT00709358.
Keywords: Sepsis, Bacteremia, PCR, Aetiological source
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Statistical analysis
The study was designed as a superiority trial. With the 
hypothesis of an effect modification by type of infection, 
the study was powered on the primary endpoint in sub-
groups of SES and FN. Assuming a documentation preva-
lence of 35–50% in SES [10] and 30% in FN, [11, 13], at 
least 480 and 440 patients in the SES and FN groups, 
respectively, were needed to show a 15% absolute differ-
ence, considering a two-sided type I error of 0.05, a type 
II error of 0.10, an intracluster correlation coefficient of 
0.01, and an 18-hospital number of clusters. Sample size 
was not estimated for SIE, since the overall number of 
cases was supposed to be lower than 150 [5].
Prevalence of the primary endpoint was compared 
between the two groups with the χ2 test, and the absolute 
risk reduction (ARR) was calculated with their 95% confi-
dence interval (CI). To account for clustering (confounding 
and effect modification by centre), a random-centre effect 
logistic regression (multilevel model with patients at level 1 
and hospital at level 2) was analysed. To estimate the inter-
vention effect, we computed the odds ratios (ORs) and their 
95% CIs in a multilevel model, taking into account the order 
of intervention to control for a potential carryover effect.
Cost‑effectiveness evaluation
The prospective economic evaluation was concur-
rent with the randomized trial, in accordance with the 
CHEERS (Consolidated Health Economic Evaluation 
Reporting Standards) statement [26]. We estimated the 
incremental cost-effectiveness of using LSF in addition 
to a standard workup from the perspective of the hospi-
tal with a 30-day time horizon [27, 28]. Effectiveness was 
defined as the primary endpoint. Hospital resources were 
valued by adjusting the 2013 average national cost of each 
patient’s diagnosis related group (DRG) with their actual 
length of stay and resources used during their hospitali-
sation. Types of resources and unit costs are described 
in Supplementary Table  2. A cost-effectiveness analysis 
was conducted to estimate incremental costs (difference 
in per-patient costs between groups) per incremental 
microbial documentation. The uncertainty of the results 
was analysed by the non-parametric bootstrap method to 
make multiple estimates of the ICER by randomly re-sam-
pling the patient population to create sub-samples. Using 
this bootstrap analysis, the scatter plot of 1,000 ICERs is 
presented on the cost-effectiveness plane [29, 30]. Data 
reporting was performed according to CONSORT (Con-
solidated Standards of Reporting Trials) guidelines [31].
Results
Patients and primary outcome
Of 1459 eligible patients, 1416 were included as 731 dur-
ing IP and 685 during CP (Fig. 1), and as 907 (64%) with 
SES, 440 (31.1%) with FN, and 69 (4.9%) with SIE. Patient 
characteristics, depicted in Table  1, were not different 
between the two periods.
During IP, MD was positive for 285/731 (39.0%) patients 
compared with 193/685 (28.2%) during CP (P  <  0.001) 
(Table 2). A higher MD rate was also significantly observed 
when excluding 41 cases with putative contaminants (e.g. 
one test positive with coagulase-negative staphylococci) 
observed at a rate of 2.7 and 3%, in CP and IP, respec-
tively. Using multilevel modelling, neither centre-effect 
(P  =  0.65) nor effect-modification by centre (P  =  0.85) 
were observed, but a significant effect with regard to the 
subgroup of infection (P  =  0.03). Kappa’s agreement 
between the results of molecular tests and those of BCs 
was poor (0.2693 ± 0.0366 SD) with only 83 patients with 
both positive molecular test and BCs in the IP.
Among patients suffering from SES, 198/464 (42.6%) 
patients had MD during IP, compared with 124/442 
(28.1%) during CP (OR 1.89, 95% CI 1.43–2.50, 
P  <  0.001). The intervention resulted in an absolute 
increase in the MD rate by 14.5% (95% CI 8.4–20.7). 
MD was significantly associated with the primary site of 
infection being other than pulmonary, with community-
acquired infection and with severity criteria (Table  3). 
Multivariate analysis adjusted for these variables did not 
change the association between the IP and the MD rate 
(OR 1.89; 95% CI 1.36–2.63, P = 0.001).
The MD rate was similar for patients with FN, and only 
a trend for an association was observed among patients 
with SIE (Table 2).
Secondary outcomes
Pathogens identified
The use of the molecular test resulted in a significantly 
higher number of patients in whom Gram-negative 
bacilli (GNB), Gram-positive cocci (GPC), or fungi 
were detected in their blood (Table  2; Fig.  2). This was 
observed in the whole population, as well as in patients 
with SES [19.6 vs. 11.5% for GNB, P  <  0.001; 23.7 vs. 
15.6% for GCP, P =  0.002; and 2.8% (13 cases) vs. 0.7% 
(3 cases) for fungi, P = 0.02, for IP and CP, respectively]. 
The detection of bacterial species not included in LSF 
(e.g., strict anaerobes, Salmonella spp., Bacillus spp. and 
others) was similar in the two periods (P = 0.18). Polymi-
crobic infections (concomitant detection of more than 
one pathogen in the blood) were more often detected 
during IP [160/731 (22%) vs. 75/685 (11%), P =  0.001). 
The pathogens detected during the two periods are 
detailed in Table 4. 
Time interval from blood collection to results
Among the patients with positive MD, the median TAT 
from blood collection to technical validation on the one 
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hand and to transmission to the clinicians on the other 
hand, were significantly shorter during IP (Table 2). It has 
to be noted that, for patients with SES, the median TAT 
was below 24  h. Results were first transmitted by tele-
phone (73.6%), computer interface (23.6%), Fax (14.5%), 
and mailing (10.9%). Interaction between laboratories 
and wards was as usual for discussion of the results.
Appropriate antimicrobial treatment
Considering the 1416 included patients, antimicrobial 
agents prescribed were beta-lactams (95.5%), amino-
glycosides (43.2%), fluoroquinolones (26.5%), glycopep-
tides (21.1%), other antibiotics (31.7%), and antifungal 
agents (17.7%), with no difference between the two 
periods (Supplementary Table 3). In this whole popula-
tion, a significantly higher number of patients received 
an appropriate therapy during IP (Table  2). However, 
when only the 478 patients with positive MD were 
considered, the rates of appropriate therapy were simi-
lar for the two periods (90.5 and 90.2%, respectively). 
An optimal treatment, i.e. more targeted towards the 
etiological microbes was observed in 263/395 (66.6%) 
patients with no difference between CP and IP (70.7 
and 63.9%, P  =  0.16) (supplementary figure). During 
IP, when 285 cases were observed as MD-positive, cli-
nicians attested they modified the antimicrobial treat-
ment according to the LSF results in 29.4% (79/269 
answers) out of which de-escalation was done for 49 
cases (62%).
Complications and mortality
Complications were observed in 362 cases (31.7% of 1142 
patients documented for complications) as an exten-
sion of the infection (n = 190, 16.6%) or a new infection 
episode (n  =  172, 15.1%), with no difference between 
the two periods [32.1% (185/577) and 29.6% (167/565), 
P  =  0.34]. Among SES patients, the 7-day mortality 
rate was 17.3% (149/863) with no significant difference 
between the two periods (18.7 vs. 15.8% in IP and CP, 
respectively; P = 0.38), even when analyses were adjusted 
for confounders (Supplementary Table  4). We checked 
that there were no relation between the positivity of the 
molecular test and mortality.
Economic evaluation
The cost-effectiveness analysis used information from all 
patients with complete primary outcome and cost data. 
Resource utilisation and costs are presented in Table  5. 
The costs associated with the molecular test were cal-
culated at an average of €475.20 per test including tech-
nician time, with each patient having an average of 1.9 
tests. There were no significant differences between the 
two periods even for investigations or number of days 
with antimicrobial treatment (13.1 days in both periods) 
(Table  5). Median total costs were €14,826 vs. €17,828, 
for IP and CP, respectively (P = 0.8). Sub-group analyses 
by disease did not show a cost difference either.
Figure  3 shows the cost-effectiveness of the molec-
ular test as a scatterplot of mean cost and effect 
Fig. 1 Flowchart of the patients according to the intervention and control periods and with regard to type of infection
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differences. The key uncertainty that drove the incre-
mental cost-effectiveness ratio was the size of the 
effectiveness effect, represented on the horizontal axis. 
The difference in effectiveness was evenly distributed 
on each side of the vertical axis for patients with FN, 
indicating no benefit during IP. The scatterplot for 
patients with SES indicated a weak dominance with 
a positive effectiveness effect and a reduced hospital 
cost as shown by the higher density below the horizon-
tal axis.
Table 1 Demographic and baseline disease characteristics
Quantitative variables are expressed as median (interquartile range); qualitative variables are expressed as number (%)
ICU intensive care unit; SOFA Sepsis-related Organ Failure Assessment; SAPS Simplified Acute Physiology Score; (/) indicates the number of missing values in each 
group
a Control period was standard care
b Study period is the period when molecular detection was added to standard care
c Other: solid tumours (n = 20), acute transformation of myeloproliferative syndrome (n = 7), allogenic (n = 1) or autologous (n = 1) stem cell transplantation, aplastic 
anemia (n = 9), myelodysplastic syndrome (n = 2)
Total population Control  perioda Intervention  periodb
n = 1416 n = 685 n = 731
Total population
 Female gender (2/0) 500 (35.4) 247 (36.2) 253 (34.6)
 Age, years 59 (48–70) 60 (48–71) 59 (48–70)
 Medical admission 1236 (87.3) 591 (86.4) 645 (88.1)
 Hospital‑acquired infection 1024 (72.3) 490 (71.6) 534 (72.9)
Type of severe infection
 Sepsis 907 (64) 442 (64.6) 465 (63.5)
 Febrile neutropenia 440 (31.1) 222 (32.5) 218 (29.8)
 Suspicion of endocarditis 69 (4.9) 21 (3.1) 48 (6.6)
Sepsis n = 907 n = 442 n = 465
 Female gender (2/0) 297 (32.8) 146 (33.2) 151 (32.5)
 Age, years 63 (51–73) 63 (51–73) 62 (51–73)
 Medical admission 737 (81.3) 354 (81.0) 383 (82.4)
 Hospital‑acquired infection 582 (64.2) 279 (63.1) 303 (65.2)
 Acquired in ICU 209 (23.0) 87 (19.7) 122 (26.2)
 Respiratory as primary site of infection 490 (62.7) 251 (65.9) 239 (59.8)
 SOFA score (n = 1/5) 8 (5–11) 8 (5–11) 8 (5–11)
 SAPS II (IQR) 46 (35–61) 44 (34–58) 47 (35–63)
Febrile neutropenia n = 440 n = 222 n = 218
 Female gender 179 (40.7) 93 (41.9) 86 (39.5)
 Age, years 54 (41–62) 53 (41–62) 54 (42–61)
 Hospital‑acquired infection 390 (88.6) 197 (88.7) 193 (88.5)
 Haematologic disease (5/8)
  Acute leukaemia 209 (49) 108 (49.8) 101 (48.1)
  Lymphoproliferative disease 178 (41.7) 89 (41.0) 89 (42.4)
  Otherc 40 (9.4) 20 (9.2) 20 (9.5)
 Treatment phase (14/21)
  First induction 110 (27.2) 63 (30.3) 47 (23.9)
  Consolidation 118 (29.1) 74 (35.6) 44 (22.3)
  Re‑induction 177 (43.7) 71 (34.1) 106 (53.8)
 Endocarditis n = 69 n = 21 n = 48
  Female gender 24 (34.8) 8 (40.0) 16 (32.7)
  Age median (IQR) years old 63 (51–71) 62.5 (48–67.5) 63 (53–73)
  Medical admission 62 (89.9) 18 (90.0) 44 (89.8)
  Preexisting valvulopathy 42 (60.9) 12 (60.0) 30 (61.2)
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Discussion
In this multicentre cluster-randomised crossover trial 
including 1416 patients, we found that adding direct 
molecular detection of pathogens in the blood of patients 
hospitalised with severe sepsis resulted in an overall 
higher microbial diagnosis rate than with conventional 
diagnosis, which was made on the basis of blood cultures. 
Moreover, the time to results was shorter in the IP, lead-
ing to bacteremia and fungemia being diagnosed in less 
than 24 h in most cases, without an increase in hospital 
costs.
In patients with severe infections, since the patho-
gen is recovered at most in 50%, the others are treated 
by empirical antimicrobial regimens without consid-
eration of appropriateness or de-escalation being pos-
sible [1, 32]. Direct detection of microbial pathogens 
in the blood was developed in the 2000s to circumvent 
culture limitations [33]. LSF was the first commercial 
kit to provide standardisation and enable comparisons 
between studies [12, 34]. Since its clinical performance 
was mostly compared with blood cultures [22], meta-
analyses concluded that it had a lack of sensitivity (68%) 
Table 2 Primary and secondary outcomes according to the study period in the intention‑to‑treat population
Control period is standard care and intervention period is the period when molecular detection was added to standard care. (/) indicates the number of patients in 
each group. Variables are expressed as number (%)
OR odds ratios; CI confidence interval; ARR absolute risk reduction
a P value of the χ2 or the Fisher’s exact test as appropriate, and of linear mixed-effects model for time to result validation and transmission, adjusted for order of 
intervention (study period first or second)
b ORs (95% CI) were estimated using a random-center effect logistic regression adjusted for order of intervention (study period first or second)
c Absolute risk reduction (ARR) was calculated from percentage values
d OR and ARR were not estimated among the total population because of significant effect modification by type of severe infection (P = 0.03)
e Number of patients with at least the detailed pathogen isolated from blood
f For details, see Table 4
Total population
n = 1416
Control period
n = 685
Intervention period
n = 731
P  valuea OR (95% CI)b ARR (95% CI)c
Primary outcome
 Microbiologically documented infec‑
tion
  Total population (n = 1416, 685/731)d 478 (33.8) 193 (28.2) 285 (39.0) <0.001 – –
  Severe sepsis (n = 907, 442/465) 322 (35.5) 124 (28.1) 198 (42.6) <0.001 1.89 (1.43–2.50) 14.5 (8.4–20.7)
  Febrile neutropenia (n = 440, 
222/218)
137 (31.1) 67 (30.2) 70 (32.1) 0.66 1.08 (0.71–1.64) –
  Suspicion of endocarditis (n = 69, 
21/48)
19 (27.5) 2 (9.5) 17 (35.4) 0.04 6.22 (0.98–39.6) 25.9 (7.4–44.4)
Secondary outcomes
 Pathogens  identifiede (n = 1416, 
685/731)
  Gram‑negative  bacillif 192 (13.6) 67 (9.8) 125 (17.1) <0.001 1.88 (1.36–2.59) 7.32 (3.8–10.84)
  Gram‑positive  coccif 288 (20.3) 124 (18.1) 164 (22.4) 0.04 1.32 (1.01–1.72) 4.33 (0.16–8.51)
  Fungi (Candida or Aspergillus)f 21 (1.5) 4 (0.6) 17 (2.3) 0.007 4.12 (1.38–12.36) 1.74 (0.51–2.97)
  Not included in the molecular test 
(anaerobes or other bacteria)f
28 (2) 10 (1.5) 18 (2.5) 0.18 1.69 (0.77–3.70) –
  Time (h) to result validation
  Total population (n = 478, 193/285) 23.6 (14.9–32) 27.5 (20.8–50.9) 22.1 (10.8–27.3) 0.006
  Severe sepsis (n = 322, 124/198) 23.2 (14.2–29.3) 27.4 (19.2–57.0) 21.6 (10.3–26.3) <0.001
  Febrile neutropenia (n = 137, 67/70) 28.5 (19.8–41.8) 31.5 (21–48.3) 26.8 (19.5–36.2) 0.97
 Time (h) to result transmission
 Total population (n = 478, 193/285) 27.5 (17.3–62) 48 (26.3–102) 23.1 (13.2–36.2) <0.001
 Severe sepsis (n = 322, 124/198) 26 (16.9–59.4) 49.5 (23.6–116) 22.9 (12.5–32) <0.001
 Febrile neutropenia (n = 137, 67/70) 38.2 (25.3–67.5) 54.8 (32.1–71.3) 30.8 (21–40.9) 0.15
Appropriate antimicrobial treatment with 
regard to the bacteremia (n = 1375, 
666/709)
395 (28.7) 157 (23.6) 238 (33.6) <0.0001 1.63 (1.29–2.07)
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and specificity (86%) leading to abandoning the test [19, 
20]. However, results which were seen as false-positives, 
i.e. low specificity, were also seen as true-positives when 
the clinical status was the gold standard (septic shock, 
for instance) or when the LSF results were compared 
with biomarkers of infection [12, 19, 35]. The presence 
of dormant or non-cultivable microbes in the blood can 
also explain the discrepancy, as well as the fact that most 
patients have already received antimicrobial agents, lead-
ing to false-negative BCs [36]. This raised the question of 
whether blood cultures can still be considered the gold 
standard for documenting bloodstream infections. It is 
also known that, with regard to clinical status, BCs show 
a lack of specificity (one-third are falsely positive due to 
contaminants, leading to excess treatment) and sensitiv-
ity (at least half of them are falsely negative in patients 
with severe infections) [9–12, 37]. We therefore decided 
to investigate the relevance of the molecular detection of 
pathogens in an interventional study with the aetiologi-
cal microbial diagnosis as the primary outcome, whatever 
the assay—blood culture or molecular test—providing 
the positive result. We hypothesised that adding molecu-
lar detection to conventional cultures would increase the 
number of cases with microbiological documentation.
The results we obtained in the CP for positive detection 
of pathogens in the blood were concordant with previ-
ous studies on large cohorts of severe sepsis, with simi-
lar severity scores and mortality rates, even with recent 
studies using the new definitions of sepsis [10, 38]. For 
FN, the positivity rate was also concordant with previous 
studies conducted on first episodes of FN, which is much 
higher than in secondary episodes [11, 13]. This high 
rate of positivity in the blood during IP is similar to that 
described in previous studies on direct molecular detec-
tion where infections were as severe as in our study [12].
Table 3 Factors affecting microbiological documentation in  the blood among  the 907 patients with  severe sepsis, uni‑
variate and multivariate analyses
Quantitative variables are expressed as median (interquartile range), qualitative variables as numbers (%). (/) Indicates the number of missing values in each group
OR odds ratio; CI confidence interval; ICU intensive care unit; SOFA Sepsis-related Organ Failure Assessment; SAPS Simplified Acute Physiology Score
a Univariate and multivariate analyses were performed using a random-center effect logistic regression adjusted for order of intervention (study period first or 
second)
b Multivariate analysis was also adjusted for the variables listed in the table
d Respiratory site of infection as compared to other sites (urinary tract, catheter-related, digestive tract, surgical site, …)
OR and 95% CI are expressed per c1 SD increase; eper one point increase; faccording to the median value (<14); and gper 1 SD increase in the log-transformed value
Microbiological documentation Univariate  analysisa Multivariate  analysisa,b
No (n = 585) Yes (n = 322) OR (95% CI) P value OR (95% CI) P value
Intervention period (yes/no) 267 (45.6) 198 (61.5) 1.93 (1.46–2.56) <0.001 1.89 (1.36–2.63) 0.001
Age, years (3/1)c 63 (51–73) 62 (50–73) 1.08 (0.94–1.24) 0.29 –
Female gender (2/0) 184 (31.6) 113 (35.1) 1.16 (0.87–1.55) 0.32 –
Medical admission 476 (81.4) 261 (81.1) 1.01 (0.70–1.44) 0.98 –
Respiratory primary site of  infectiond (87/39) 359 (72.2) 131 (46.1) 0.33 (0.23–0.44) <0.001 0.35 (0.25–0.47) <0.001
Hospital acquired infection 399 (68.2) 183 (56.8) 0.61 (0.46–0.82) <0.001 0.55 (0.40–0.76) <0.001
Severity of the sepsis at inclusion
 SOFA score (n = 5/1)e 8 (5–11) 8 (5–12) 1.05 (1.01–1.08) 0.005 1.06 (1.02–1.10) 0.002
 Glasgow score (n = 43/23)f 14 (7–15) 14 (7–15) 1.17 (0.88–1.56) 0.29 –
 SAPS (n = 7/6)g 45 (34–58) 49 (36–65) 1.16 (1.00–1.34) 0.047 –
Septic shock 318 (54.4) 187 (58.1) 1.16 (0.88–1.53) 0.30 –
Fig. 2 Venn diagram presenting the microbial diagnosis given by 
blood cultures (BC) and the molecular test (LSF) for patients during 
the intervention period. GNB Gram‑negative bacilli (enterobacte‑
ria, acinetobacter and pseudomonades), GPC Gram‑positive cocci 
(staphylococci, streptococci and enterococci), blue circle BC positive 
cases, green circle positive molecular test. Cases could be diagnosed 
with more than one pathogen
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Table 4 List and  number (%) of  the microbial  pathogensa per  species that  were detected in  the  bloodb during  the two 
periods
Microbial pathogen group and species Control period Intervention period Total
Gram‑negative bacilli (GNB)
 Enterobacteria 66 (29.5) 116 (32.6) 182 (31.4)
  Citrobacter freundii 1 0 1
  Citrobacter koseri 1 0 1
  Enterobacter 11 29 40
  Escherichia coli 31 56 87
  Klebsiella 18 28 46
  Proteus mirabilis 1 1 2
  Providencia 0 1 1
  Salmonella enterica 2 0 2
  Serratia marcescens 1 1 2
 Pseudomonas and other strict aerobes bacteria 9 (4.0) 26 (7.3) 35 (6.0)
  Acinetobacter sp. 1 1 2
  Pseudomonas aeruginosa 8 21 29
  Pseudomonas putida 0 1 1
  Stenotrophomonas maltophilia 0 3 3
Gram‑positive cocci (GPC)
 Staphylococci 78 (34.8) 104 (29.2) 182 (31.4)
  Staphylococcus aureus 17 41 58
  Coagulase negative staphylococci 61 63 124
 Streptococci and enterococci 56 (25.0) 77 (21.6) 133 (22.9)
  Nonhaemolytic streptococci 24 33 57
  Haemolytic streptococci 2 1 3
  Pneumococci 15 20 35
  Enterococcus faecalis 7 15 22
  Enterococcus faecium 5 8 13
  Other enterococci 3 0 3
 Strict anaerobic bacteria 5 (2.2) 8 (2.2) 13 (2.25)
  Bacteroides fragilis 0 3 3
  Bacteroides merdae 1 0 1
  Bacteroides sp. 1 0 1
  Bacteroides thetaiotaomicron 1 0 1
  Bacteroides vulgatus 1 0 1
  Bilophila wadsworthia 1 1 2  
  Desulfovibrio sp. 0 1 1
  Clostridium clostridioforme 0 1 1
  Clostridium perfringens 0  1 1
  Fusobacterium nucleatum 0  2 2
 Other bacteria 6 (2.7) 7 (2.0) 13 (2.25)
  Bacillus sp. 2 0 2
  Corynebacterium sp. 1 3 4
  Coxiella sp. 1 0 1
  Haemophilus influenzae 1 2 3
  Lactobacillus sp. 1 1 2
  Neisseria sp. 0 1 1
 Fungi
 Candida 4 (1.8) 16 (4.5) 20 (3.5)
  Candida albicans 2 8 10
1621
Because the aetiological microbes were more often 
documented in the IP, we looked at the consequences on 
the prescription of antimicrobial agents to treat the infec-
tion. We did not observe significant differences in pre-
scription, either quantitatively (number of patients with 
treatment and cost per patient) or qualitatively (antimi-
crobial spectra), even for SES cases. This was probably 
because the treatment was not protocolled according to 
the pathogen identification, and the LSF test did not pro-
vide susceptibility results more than methicillin resist-
ance of staphylococci [1, 3, 25]. It may also be due to the 
intervention itself, since polymicrobial infections and 
fungal infections were more often diagnosed, requiring 
broad-spectrum antibacterial agents and, in some cases, 
the addition of antifungal agents. Lastly, we did not detail 
the dosage of the agents, which was shown recently to be 
underestimated in most patients with severe infections 
[39]. Patients were managed under standard care condi-
tions and, although the therapeutic approach may have 
varied between investigators, ward, and hospital cen-
tres, the results were mostly dependent upon the type of 
infection, and not the centre. The outcome was similar 
between the two periods, with a mortality rate concord-
ant with the severity scores at inclusion [1, 10].
Because most molecular tests are more expensive than 
blood cultures, we investigated the cost of implement-
ing systematic molecular detection in blood in addition 
to standard care. In a previous study, the cost was lower 
(€32,228 vs. €42,198) for 48 patients having LSF plus BC 
versus 54 patients having only BC [40]. In our study, the 
addition of LSF provided only a trend for lower hospi-
tal costs and higher effectiveness (i.e., microbiological 
diagnostic yield) for patients with SES. This was prob-
ably because the length of ICU stay was not affected by 
the earlier identification of micro-organisms, as also 
observed in other studies [8].
Limitations and strengths
There are two main limitations of our study. The first 
is that we present our results in 2016 when sepsis 
definitions have changed [41]. The strengths of our study 
remain since the patient characteristics were as severe 
as recent cohorts examined with the new sepsis criteria 
[8, 38]. The second limitation is the LSF test itself since 
it does not provide antimicrobial susceptibility testing 
results, as well as the most recent kits of this kind [42, 
43]. Consequently, although MD was obtained for more 
patients and more rapidly during IP, we did not observe 
any difference in the antimicrobial treatment and out-
comes. A recent controlled study showed that reducing 
TAT to pathogen identification in BCs, without specific 
AST as in our study, was able to decrease the prescrip-
tion of broad-range antimicrobials and to increase de-
escalation and appropriate escalation, at the condition 
that antibiotic stewardship is also provided [44], which 
was not done in our study. Minor weaknesses of the study 
concerns the suspicion of endocarditis, because the num-
ber of patients was too low to yield any conclusions since 
infective endocarditis infections are fairly rare (1/100,000 
cases observed yearly) and their diagnosis, according to 
Duke and Li definitions, already includes microbiologi-
cal results from BCs and from culture of removed valves 
[4]. Here, we aimed to include patients before diagnosis 
as we sought to include more documentation (i.e., we 
increased the number of cases with definite infective 
endocarditis). Although there was a trend in association, 
the numbers of patients with SIE were too small to show 
significant differences and a specific study for this indi-
cation is needed. Although we were disappointed by the 
results for patients with a first episode of FN, they con-
firmed the results of previous smaller studies [11, 34]. It 
was suggested that, in FN, the diagnostic yield of molecu-
lar detection could be higher in patients already receiv-
ing antimicrobial agents, i.e., at the second or later febrile 
episode, rather than in naïve patients. Regarding the lack 
of benefit for documenting FN, other assays should be 
explored and the infectious nature of the associated fever 
may need to be reconsidered.
The strengths of our study are the following. This is 
the first randomised interventional study on the use of 
a Multiple microbial pathogens could be isolated from one patient
b Pathogens were detected by blood cultures or by the molecular test
Table 4 continued
Microbial pathogen group and species Control period Intervention period Total
  Candida glabrata 1 2 3
  Candida krusei 0 1 1
  Candida parapsilosis 0 1 1
  Candida sp. 1 4 5
 Aspergillus fumigatus 0 2 (0.6) 2 (0.3)
 Total 224 (100) 356 (100) 580 (100)
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Table 5 Cost (in euros) in total population for the control and intervention periods
a P < 0.05 based on Student’s t test for the mean
Measured parameters Control period (n = 560) Intervention period (n = 555) P  valuea
Mean cost ± SD (€) Average number 
per patient ± SD
Mean cost ± SD (€) Average number 
per patient ± SD
Total population
 SeptiFast LightCycler test 8 0.02 892 ± 207 2 ± 0.4 NA
 Blood cultures 125 ± 155 6 ± 7 109 ± 121 5 ± 6 0.25
 Other diagnostic procedures 648 ± 481 17 ± 10 590 ± 454 15 ± 9 0.5
 Anti‑infective treatments 837 ± 2,304 4 ± 2 868 ± 2,250 4 ± 2 0.62
 Length of hospital stay (days) 17 ± 11 17 ± 11 0.34
 Total cost per patient 18,653 ± 15,966 18,118 ± 17,775 0.75
Severe sepsis (n patients) 370 336
 SeptiFast LightCycler test 3 0.01 904 ± 230 2 ± 0.5 NA
 Blood cultures 110 ± 149 5 ± 7 100 ± 113 5 ± 5 0.32
 Other diagnostic procedures 735 ± 538 19 ± 10 666 ± 473 17 ± 9 0.17
 Anti‑infective treatments 635 ± 1,884 4 ± 2 676 ± 2,175 4 ± 2 0.79
 Length of hospital stay (days) 18 ± 12 16 ± 12 0.18
 Total cost per patient 20,995 ± 17,593 19,329 ± 16,355 0.09
Febrile neutropenia (n patients) 176 188
 SeptiFast LightCycler test 22 0.12 882 ± 165 2 ± 0.4 NA
 Blood cultures 160 ± 168 7 ± 8 132 ± 137 6 ± 6 0.08
 Other diagnostic procedures 448 ± 283 19 ± 9 423 ± 325 13 ± 9 0.22
 Anti‑infective treatments 1,228 ± 2,997 4 ± 2 1,297 ± 2,444 4 ± 2 0.98
 Length of hospital stay (days) 16 ± 9 16 ± 9 0.72
 Total cost per patient 14,033 ± 10,844 16,230 ± 13,361 0.07
Fig. 3 Incremental cost and effectiveness of the molecular test when compared to standard workup: cost effectiveness plane for incremental costs 
and difference in 24‑h documentation for neutropenic patients and patients with severe sepsis
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direct molecular detection of pathogens in the blood by 
a commercial test. The originality of this study is that we 
did not compare results of the molecular test to those of 
blood cultures taken as the gold standard, but instead 
evaluated what direct molecular testing brings in stand-
ard care with regard to clinical status assessing the pri-
mary outcome of microbial diagnosis. Strengths of the 
study also include its size and design. The study was 
planned as a cluster-randomised trial because of practical 
(cost of equipment and technical staff) and organisational 
(training of laboratory technicians on-site) constraints. 
This design allowed the optimisation of compliance 
with the assigned strategy. A common pitfall of cluster-
randomised trials is an imbalance in patient character-
istics and patient management. Therefore, we planned a 
crossover design to minimise imbalance between groups, 
and randomised the order of intervention. This crossover 
design was suitable because there was low risk of a carry-
over effect. We obtained comparable baseline character-
istics of severe sepsis groups during the two periods and 
adjustment for potential confounders did not change the 
results of the crude analysis. The strengths also include 
the molecular test itself since the main limiting factor 
of molecular tests in direct diagnosis is their analytical 
sensitivity, i.e. their ability to detect bacterial and fungal 
DNA without natural amplification by culture. LSF is one 
of the rare tests that can reproducibly detect 100  CFU/
ml. The future test should be as sensitive as LSF but 
should detect resistance genes.
Conclusions
Our study demonstrated, in a multicentre randomised 
controlled trial, that performing molecular detection of 
pathogens in addition to standard care of blood cultures, 
increases the number of septic patients with microbial 
diagnosis, and shortens the time to start a species-specific 
antimicrobial therapy. A step further is now necessary 
with molecular antimicrobial resistance testing combined 
with protocolled strategy with regard to epidemiological 
data of the centre or stewardship for antimicrobial agents. 
This can bring more impact, especially in cases of infec-
tion caused by multidrug-resistant pathogens [44].
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